Skip to Content

ASH 2023: The Impact of Fitness and Dose Intensity on Safety and Efficacy Outcomes after Venetoclax-Obinutuzumab in Previously Untreated CLL

A comprehensive analysis of Venetoclax-Obinutuzumab (Ven-Obi) in treating chronic lymphocytic leukemia (CLL) reveals its effectiveness and tolerability across different patient profiles.

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top